News & Events

Can Precision Medicine Crack Another KRAS Code? New Study Targets a Rare Lung Cancer Mutation-but the Clinical Test Still Lies Ahead

Can Precision Medicine Crack Another KRAS Code? New Study Targets a Rare Lung Cancer Mutation-but the Clinical Test Still Lies Ahead

Divarasib Outperforms First-Gen Competitors in Pretreated KRAS G12C NSCLC

Divarasib Outperforms First-Gen Competitors in Pretreated KRAS G12C NSCLC

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation

New Drug Combo for KRAS Lung Cancer: Hope for Patients

New Drug Combo for KRAS Lung Cancer: Hope for Patients

Divarasib Outperforms First-Gen Competitors in Pretreated KRAS G12C NSCLC

Divarasib Outperforms First-Gen Competitors in Pretreated KRAS G12C NSCLC

Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase III NSCLC Trial

Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase III NSCLC Trial

Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors in Phase III NSCLC Trial

Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors in Phase III NSCLC Trial

Divarasib Improves Survival Vs Approved KRAS G12C Inhibitors in NSCLC

Divarasib Improves Survival Vs Approved KRAS G12C Inhibitors in NSCLC